Trudeau govt to work with China in testing new COVID-19 vaccine from aborted babies
(LifeSiteNews) — Canada’s largest federal research and development organization announced that it will be teaming up with a Chinese vaccine company with the hopes of testing a new trial coronavirus vaccine in Canada, which, one watchdog is warning, is made from aborted fetal cell lines.
In a press release sent out on May 12, the National Research Council (NRC) announced a collaboration with the Chinese firm CanSino Biologics Inc. (CanSinoBIO), to test its trial coronavirus vaccine, known as Ad5-nCoV, in Canada.
Alan Moy M.D., founder and scientific director of the John Paul II Medical Research Institute and CEO of Cellular Engineering Technologies, confirmed for LifeSiteNews that Ad5-nCoV was indeed developed unethically. It uses the NRC’s HEK293 cell line, which was developed by the NRC and was made from aborted fetal cell lines.
“Since it’s using an adenovirus replication-defective vector, it is using HEK293. HEK293 is an aborted fetal cell line,” said Moy to LifeSiteNews.
Moy says the Ad5-nCoV vaccine being promoted by the Canadian government in collaboration with China may not prove to be very effective.
“I don’t envy Canadians. Your government and PM have mandated draconian policies that are anti-life,” said Moy.
“Another problem is that there is a high incidence of immunity against Ad5, so chances are high that patients will reject the vaccine. Not a good vaccine solution if pro-life or pro-choice,” added Moy, referencing an abstract to support his claim.
The trial vaccine Ad5-nCoV was co-developed by the Beijing Institute of Biotechnology and CanSinoBIO. Ad5-nCoV has already been used in initial human trials since mid-March in China. According to the NRC press release, it is the world’s first phase 2 coronavirus vaccine, which is approved to “safely” be used in human tests.
CanSinoBIO is now filling out the needed paperwork to get Ad5-nCoV approved for testing in Canada. Before this can happen, Health Canada will still have to approve the trial.
Mr. Iain Stewart, president of the National Research Council of Canada, was quoted as saying in the press release that the “vaccine candidate holds great promise,” adding that the “NRC is proud of our ongoing partnership with CanSino Biologics.”
Dr. Xuefeng Yu, chairman and CEO of CanSinoBIO said in the press release that his firm has “strong connections to Canada, and we’re proud to be building on past successes and continuing our ongoing partnership with the NRC to address health needs on a global scale.”
The NRC said in its press release that it hopes its collaboration with CanSinoBIO will help it “to advance a scale-up production process for the vaccine candidate, using its proprietary HEK293 cell line.”
The government of Canada announced that it would be providing $44 million to support and upgrade the NRC’s Montreal location.
In April, the pro-abortion prime minister of Canada, Justin Trudeau, said he needed time to “reflect” about the possibility of making a coronavirus vaccine mandatory in Canada if and when it becomes available.
In 2019, the JP2MRI started its “Campaign for Cures” with the goal being to “develop ethical human cell lines that can be used in the bio-manufacturing of vaccines, protein therapeutics, gene therapy, and cell therapy.”
full story at https://www.lifesitenews.com/news/trudeau-govt-to-work-with-china-in-testing-new-covid-19-vaccine-from-aborted-babies